EQUITY RESEARCH MEMO

DPT Laboratories

Generated 5/10/2026

Executive Summary

Conviction (model self-assessment)60/100

DPT Laboratories, a subsidiary of Viatris, is a contract development and manufacturing organization (CDMO) with over 80 years of experience specializing in semi-solid and liquid dosage forms. Based in San Antonio, Texas, the company offers integrated services from pre-formulation and clinical trial supply to commercial-scale cGMP manufacturing. As a key player in the pharmaceutical outsourcing market, DPT benefits from the growing trend of drug developers seeking external partners to reduce costs and accelerate timelines. Its long-standing expertise in complex formulations positions it well to serve both small and large pharma clients, particularly in the dermatology, podiatry, and ophthalmology segments. The CDMO industry is poised for steady growth driven by increasing R&D spending and the outsourcing of manufacturing by biotech firms, which should provide a tailwind for DPT's business.

Upcoming Catalysts (preview)

  • Q4 2026Capacity Expansion or New Facility Announcement65% success
  • Q1 2027Major Client Contract Win or Partnership Extension50% success
  • Q2 2027Viatris Strategic Review of Subsidiaries30% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)